Streetbeat News

Products Services

TCNNF

TDR Research has rated Trulieve Cannabis (OTC:TCNNF) a 'Buy', citing strong financial health and growth potential. The report projects a 46% upside in stock price, with 2024 revenue estimates of $1.20 billion and an EBITDA of $298.8 million. Despite some challenges, anticipated regulatory changes in the cannabis industry could further enhance Trulieve's prospects.

Portfolio Pulse from Nicolás Jose Rodriguez

May 30, 2024 | 6:30 pm

QCOM

Qualcomm's CFO announced a new focus on on-device AI, marking a significant shift from their traditional wireless technology. The company introduced the Snapdragon X elite platform for PCs and highlighted the role of AI in the automotive industry.

Portfolio Pulse from Abbey Higginbotham

May 30, 2024 | 6:29 pm

CRM

NVDA

Jim Cramer attributes the recent 20% drop in Salesforce (CRM) stock to the rapid advancement of AI, particularly driven by Nvidia (NVDA). Salesforce reported its first revenue miss in over a decade and issued weak guidance for the next quarter. Cramer suggests that companies are reassessing their software spending due to the potential for AI to reduce the need for human labor.

Portfolio Pulse from Adam Eckert

May 30, 2024 | 6:26 pm

PLNH

Planet 13, the operator of the world's largest cannabis dispensary, has added a Koolsville Tattoo location to its premises in Las Vegas. This collaboration offers a unique experience by combining cannabis products with tattoo services. The move aims to increase foot traffic and offset lease costs for Planet 13, while providing Koolsville Tattoo with a prime location near the Las Vegas Strip.

Portfolio Pulse from Javier Hasse

May 30, 2024 | 6:24 pm

TECK

Glencore has postponed discussions on spinning off its coal business until after the closure of its $6.93 billion acquisition of Teck Resources' steelmaking coal assets. The decision to potentially spin off the coal unit will be influenced by shareholder consultations, especially considering environmental and social governance concerns.

Portfolio Pulse from Stjepan Kalinic

May 30, 2024 | 6:19 pm

BBY

BIRK

BURL

CRDO

CRM

DIA

GLD

HPQ

HRL

IWM

KSS

NTNX

OKTA

PATH

PSTG

QQQ

SPY

TAN

TLT

XLK

XLRE

Wall Street saw a decline in major large-cap indices due to downturns in tech and communication services sectors. Investors shifted focus to small caps, real estate, and solar stocks. The second estimate of Q1 GDP growth was revised down to 1.3%. The S&P 500, Nasdaq 100, and Dow Jones Industrial Average fell, while the iShares Russell 2000 ETF and iShares 20+ Year Treasury Bond ETF rose. Salesforce plummeted 20% after missing revenue expectations, while HP Inc. rose 19% on strong results. Other notable movers included Kohl Corp., Dollar General, Best Buy, Hormel Foods, Burlington Stores, Birkenstock, Agilent Technologies, Pure Storage, Okta, Nutanix, Ui Path, and Credo Technology.

Portfolio Pulse from Piero Cingari

May 30, 2024 | 5:57 pm

The FAA Administrator has stated that Boeing has not requested to increase the production cap for the 737 Max, and no preliminary discussions have been held regarding this matter.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 5:52 pm

TSLA

TSLL

TSLS

Tesla is seeking final approval from the Chinese government to deploy Full Self-Driving (FSD) cars in China. The rollout will start with employee vehicles and, if successful, expand to customers. This move could boost Tesla's sales and pressure other EV startups. Tesla's FSD software will be available for a one-time purchase or a monthly subscription. The company aims to collect more data to develop true FSD and eventually launch a global robotaxi service. Direxion offers ETFs for both bullish and bearish investors on Tesla.

Portfolio Pulse from Johnny Rice

May 30, 2024 | 5:51 pm

UAL

The FAA has granted United Airlines permission to take new aircraft deliveries. This announcement was made by FAA Administrator Mike Whitaker during a press conference.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 5:47 pm

CPRX

Catalyst Pharmaceuticals has received FDA approval to increase the maximum daily dose of FIRDAPSE for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) from 80 mg to 100 mg.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 5:42 pm